Subclinical Hypothyroidism After 225Ac-DOTATATE Therapy in a Case of Metastatic Neuroendocrine Tumor: Unknown Adverse Effect of PRRT
Abstract
ABSTRACT: Radiation-induced thyroid dysfunction is very rarely associated with peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors using β-emitting radionuclides. With the emergence of α radionuclide such as 225Ac, PRRT using these radionuclides has shown better results; however, data on the toxicity profile are limited. This is a case report describing the thyroid dysfunction developed in a patient with inoperable metastatic neuroendocrine tumor with unknown primary after PRRT using 225Ac-DOTATATE, which has never been reported previously.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a NET-CUP case report, thyroid dysfunction developed after 225Ac-DOTATATE therapy in a patient with NET with unknown primary.
“First case report demonstrating thyroid dysfunction developed after 225Ac-DOTATATE therapy in a patient with NET with unknown primary.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [165]
Cites
Zaknun, J. J., Bodei, L., Mueller‐Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O'Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 823 · see citing works
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215 · see citing works
Lin, Z., Yang, Z., He, B., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200310 · Cited by 47 · see citing works
Radiation-related thyroid autoimmunity and dysfunction
Nagayama, Y. (2017) · Journal of Radiation Research · doi:10.1093/jrr/rrx054 · Cited by 45 · see citing works
Zhang, J., Kulkarni, H., & Baum, R. P. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002915 · Cited by 41 · see citing works
Mizokami, T., Hamada, K., Maruta, T., et al. (2016) · European Thyroid Journal · doi:10.1159/000448398 · Cited by 11 · see citing works
Gubbi, S., Al-Jundi, M., Rivero, J. D., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.587065 · Cited by 9 · see citing works
Pathologic Effects of Radiation on the Thyroid Gland
(2016) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681082219116010012 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
- Authors
- Kavanal, A. J., Satapathy, S., Sood, A., Khosla, D., & Mittal, B. R.
- Affiliations
- Nuclear Medicine
- Post Graduate Institute of Medical Education and Research (IN)
- Corresponding author
- Kavanal, Anwin Joseph
- Satapathy, Swayamjeet
- Sood, Ashwani
- Mittal, Bhagwant Rai
- Venue
- Clinical Nuclear Medicine
- Published
- 2021-09-10
- Volume
- 47
- Issue
- 2
- Pages
- e184-e186
- ISSN
- 0363-9762 (ISSN-L)
- 1536-0229
- OpenAlex
- W3196698872
- Cited by
- 11
- References
- 8
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 2
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- subclinical hypothyroidism, peptide receptor radionuclide therapy, alpha-emitting radionuclides, radiation-induced thyroid dysfunction, metastatic neuroendocrine tumors, treatment toxicity
- MeSH terms
- Actinium, Humans, Hypothyroidism, Organometallic Compounds, Radionuclide Imaging, Octreotide, Neuroendocrine Tumors, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
